Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GANX
stocks logo

GANX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.144
+80%
--
--
-0.160
-0%
--
--
-0.165
-13.16%
Estimates Revision
The market is revising No Change the revenue expectations for Gain Therapeutics, Inc. (GANX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 98.86%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.35%
In Past 3 Month
Stock Price
Go Up
up Image
+98.86%
In Past 3 Month
Wall Street analysts forecast GANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GANX is 6.80 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast GANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GANX is 6.80 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.500
sliders
Low
5.00
Averages
6.80
High
8.00
Current: 3.500
sliders
Low
5.00
Averages
6.80
High
8.00
BTIG
Buy
downgrade
$9 -> $5
2025-10-16
Reason
BTIG
Price Target
$9 -> $5
2025-10-16
downgrade
Buy
Reason
BTIG lowered the firm's price target on Gain Therapeutics to $5 from $9 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.
Roth Capital
Buy
maintain
$7 -> $6
2025-08-12
Reason
Roth Capital
Price Target
$7 -> $6
2025-08-12
maintain
Buy
Reason
Roth Capital lowered the firm's price target on Gain Therapeutics to $6 from $7 and keeps a Buy rating on the shares after meeting with its CEO to discuss the company's Phase 1b study evaluating lead candidate GT-02287 in Parkinson's disease. The CSF biomarker data expected in Q4 makes most sense "to gain preliminary conviction" as it better capitulates pathological changes associated with iPD and GBA1-PD vs. serum biomarker analysis, the analyst tells investors in a research note.
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$6
2025-03-28
Reason
Chardan Capital
Keay Nakae
Price Target
$6
2025-03-28
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$8
2025-03-17
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$8
2025-03-17
Reiterates
Strong Buy
Reason
Scotiabank
Louise Chen
Buy
Initiates
$12
2025-03-07
Reason
Scotiabank
Louise Chen
Price Target
$12
2025-03-07
Initiates
Buy
Reason
Roth MKM
Boobalan Pachaiyappan
Strong Buy
Maintains
$7
2024-12-24
Reason
Roth MKM
Boobalan Pachaiyappan
Price Target
$7
2024-12-24
Maintains
Strong Buy
Reason
Roth MKM keeps a Buy rating and $7 price target on Gain Therapeutics after the company received approval from Australian regulators to begin GT-02287 evaluation in Parkinson's disease patients. The firm believes that the Phase 1b study will deliver positive findings regarding safety, preliminary biochemical efficacy, and tolerability, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Gain Therapeutics Inc (GANX.O) is -5.43, compared to its 5-year average forward P/E of -3.12. For a more detailed relative valuation and DCF analysis to assess Gain Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.12
Current PE
-5.43
Overvalued PE
-1.81
Undervalued PE
-4.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2421.90
Current PS
0.00
Overvalued PS
10014.99
Undervalued PS
-5171.20
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GANX News & Events

Events Timeline

(ET)
2025-11-20
07:04:19
Gain Therapeutics shares findings on GT-02287
select
2025-11-12 (ET)
2025-11-12
07:13:25
Gain Therapeutics announces Q3 EPS of 15 cents, matching consensus expectations.
select
2025-09-18 (ET)
2025-09-18
07:47:36
Gain Therapeutics Launches Phase 1b Extension Study for GT-02287 in Parkinson's Disease
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-18NASDAQ.COM
Gain Therapeutics (GANX) Receives Upgrade to Buy: Key Information You Need to Know

  • Zacks Rank Upgrade: Gain Therapeutics, Inc. (GANX) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.

  • Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock movements, suggests that the recent increase in earnings estimates for Gain Therapeutics could lead to buying pressure and a potential rise in stock value.

  • Market Positioning: The upgrade places Gain Therapeutics in the top 20% of Zacks-covered stocks, reflecting its strong earnings estimate revision feature and potential for market-beating returns.

  • Quantum Computing Insights: The article also highlights the rapid advancement of quantum computing, with major tech companies integrating the technology, and mentions a report by Senior Stock Strategist Kevin Cook on stocks poised to dominate this emerging field.

[object Object]
Preview
9.5
11-12SeekingAlpha
Gain Therapeutics Reports GAAP EPS of -$0.15, Exceeding Expectations by $0.01

  • Q3 Earnings Report: Gain Therapeutics (GANX) reported a Q3 GAAP EPS of -$0.15, beating expectations by $0.01.

  • Cash Position: As of September 30, 2025, the company had cash and cash equivalents of $8.8 million, down from $10.4 million at the end of 2024.

  • Valuation Insights: Despite recent reports of functional improvement in Parkinson's Disease (PD) patients, Gain Therapeutics' valuation remains low.

  • Seeking Alpha Rating: The company has received a Quant Rating from Seeking Alpha, reflecting its financial performance and market position.

[object Object]
Preview
1.0
10-09Newsfilter
Gain Therapeutics to Hold Virtual KOL Event Focused on GT-02287 for Parkinson's Disease

  • KOL Event Announcement: Gain Therapeutics will host a virtual event on October 14, 2025, featuring experts discussing biomarkers and clinical endpoints related to their drug candidate GT-02287 for Parkinson's disease.

  • GT-02287 Clinical Trial Update: The Phase 1b trial of GT-02287 has shown promising safety and tolerability results, with improvements in Parkinson's disease symptoms, and aims to evaluate its effects on patients with or without a GBA1 mutation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Gain Therapeutics Inc (GANX) stock price today?

The current price of GANX is 3.5 USD — it has increased 5.42 % in the last trading day.

arrow icon

What is Gain Therapeutics Inc (GANX)'s business?

Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

arrow icon

What is the price predicton of GANX Stock?

Wall Street analysts forecast GANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GANX is 6.80 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Gain Therapeutics Inc (GANX)'s revenue for the last quarter?

Gain Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Gain Therapeutics Inc (GANX)'s earnings per share (EPS) for the last quarter?

Gain Therapeutics Inc. EPS for the last quarter amounts to -0.15 USD, decreased -11.76 % YoY.

arrow icon

What changes have occurred in the market's expectations for Gain Therapeutics Inc (GANX)'s fundamentals?

The market is revising No Change the revenue expectations for Gain Therapeutics, Inc. (GANX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 98.86%.
arrow icon

How many employees does Gain Therapeutics Inc (GANX). have?

Gain Therapeutics Inc (GANX) has 23 emplpoyees as of December 05 2025.

arrow icon

What is Gain Therapeutics Inc (GANX) market cap?

Today GANX has the market capitalization of 134.62M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free